Jubilant Ingrevia (JUBLINGREA) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 saw healthy sequential performance, driven by specialty chemicals and cost initiatives over the past three quarters.

• Pharmaceutical and nutrition segments showed strong demand, especially in regulated markets (North America, Europe, Japan).

• USFDA inspection at Bharuch facility completed with zero 483 observations, supporting growth in regulated nutraceutical markets.

• Acetyls segment faced pressure due to lower paracetamol demand and higher freight costs, while agrochemicals showed marginal improvement as inventory issues eased.

• Focus remains on customer-centricity, ramping up new plants, cost control, and sustainability initiatives.

Financial highlights

• Q1 FY25 consolidated revenue was INR 1,024 crore, down from INR 1,075 crore in Q1 FY24, mainly due to lower chemical intermediate revenue.

• EBITDA for the quarter stood at INR 119 crore, up 18% sequentially, driven by margin improvements in specialty chemicals and nutrition.

• Net profit for Q1 FY25 was INR 49 crore, up 67% sequentially but down 15% year-over-year.

• Net debt as of June 30, 2024, was INR 677 crore; net debt to equity ratio at 1.5x (TTM EBITDA basis).

• Net working capital to turnover reduced to 18.6% (from 20% YoY); working capital days down to 68 from 73.

Outlook and guidance

• Specialty chemical EBITDA margins expected to remain above 20%, with aspirations to reach 23-25% as product mix improves.

• Nutrition margins projected to rise to 17-18%+ with new food and cosmetic grade products; steady state feed segment margins at 12-13%.

• CDMO business targeted to grow 25-30% YoY, with pharma steady at 20-25% and agro segment growth expected to be lumpy.

• Company maintains its Pinnacle 3-4-5 vision: 3x revenue and 4x EBITDA in 5 years, aiming for 20%+ company-level EBITDA margin.

• Continued focus on cost control, ramping up new plants, and investing in high-potential product categories.